BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
Number Citing Articles
1 Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU. Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25:390-9. [PMID: 31146508 DOI: 10.3350/cmh.2018.0103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
2 Kim TY, Lee JG, Sohn JH, Kim JY, Kim SM, Kim J, Jeong WK. Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis. Yonsei Med J 2016;57:138-45. [PMID: 26632394 DOI: 10.3349/ymj.2016.57.1.138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Lee DY, Park JW, Kim TH, Lee JH, Kim BH, Woo SM, Kim SS, Lee WJ, Kim DY, Kim CM. Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. Strahlenther Onkol 2015;191:835-44. [PMID: 26174506 DOI: 10.1007/s00066-015-0873-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
4 Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136:1458-1467. [PMID: 25099027 DOI: 10.1002/ijc.29126] [Cited by in Crossref: 69] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
5 Lee YS, Kim BH, Kim BC, Shin A, Kim JS, Hong SH, Hwang JA, Lee JA, Nam S, Lee SH, Bhak J, Park JW. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget 2015;6:16449-60. [PMID: 25965825 DOI: 10.18632/oncotarget.3758] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
6 Jung J, Kong M, Hong SE. Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis. Onco Targets Ther 2014;7:1769-75. [PMID: 25328410 DOI: 10.2147/OTT.S69618] [Reference Citation Analysis]
7 Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer 2015;15:236. [PMID: 25885683 DOI: 10.1186/s12885-015-1273-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
8 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
9 Shin SK, Park SY, Jung YK, Kim EJ, Lee HN, Lee JJ, Kwon OS, Choi DJ, Kim YS, Kim JH. [Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience]. Korean J Gastroenterol 2015;65:105-11. [PMID: 25716713 DOI: 10.4166/kjg.2015.65.2.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Sinn DH, Gwak GY, Cho J, Paik SW, Yoo BC. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One. 2014;9:e112184. [PMID: 25372403 DOI: 10.1371/journal.pone.0112184] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
11 Bae B, Song SK, Choi E, Chung CW, Park Y. Secondarily estimated cure fraction and five-year recurrence-free conditional survival probabilities among patients undergoing surgical resection for hepatocellular carcinoma presenting with minor gross vascular invasion. World J Surg Oncol 2021;19:222. [PMID: 34311741 DOI: 10.1186/s12957-021-02331-1] [Reference Citation Analysis]
12 Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-43. [PMID: 21739567 DOI: 10.1002/lt.22369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
13 Jiang W, Zeng ZC. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncology. 2013;84 Suppl 1:69-74. [PMID: 23428862 DOI: 10.1159/000345893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
14 Dionisi F, Guarneri A, Dell'Acqua V, Leonardi M, Niespolo R, Macchia G, Comito T, Amichetti M, Franco P, Cilla S, Caravatta L, Alongi F, Mantello G. Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology. Radiol Med 2016;121:735-43. [PMID: 27255503 DOI: 10.1007/s11547-016-0650-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Park SK, Jung YK, Chung DH, Kim KK, Park YH, Lee JN, Kwon OS, Kim YS, Choi DJ, Kim JH. Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience. Korean J Intern Med. 2013;28:428-438. [PMID: 23864801 DOI: 10.3904/kjim.2013.28.4.428] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
17 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
18 Yang DS, Yoon WS, Lee JA, Lee NK, Lee S, Kim CY, Yim HJ, Lee SH, Chung HH, Cha SH. The effectiveness of gadolinium MRI to improve target delineation for radiotherapy in hepatocellular carcinoma: a comparative study of rigid image registration techniques. Phys Med 2014;30:676-81. [PMID: 24870246 DOI: 10.1016/j.ejmp.2014.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Nam BH, Park JW, Jeong SH, Lee SS, Yu A, Kim BH, Kim WR. Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). PLoS One 2015;10:e0138374. [PMID: 26488298 DOI: 10.1371/journal.pone.0138374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Kim DY, Park JW, Kim TH, Kim BH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim CM. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol. 2017;122:122-129. [PMID: 28034460 DOI: 10.1016/j.radonc.2016.12.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
21 Rim MY, Kwon OS, Ha M, Kim JS, Ko KI, Kim DK, Jang PK, Han JY, Park PH, Jung YK, Choi DJ, Kim YS, Kim JH. [Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma]. Korean J Gastroenterol 2014;63:292-8. [PMID: 24870301 DOI: 10.4166/kjg.2014.63.5.292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kim JM, Kwon CH, Joh JW, Sinn DH, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy: a matched study. Medicine (Baltimore). 2015;94:e450. [PMID: 25674733 DOI: 10.1097/md.0000000000000450] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
23 Goh MJ, Kang W, Kim KM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scand J Gastroenterol 2021;:1-8. [PMID: 34731072 DOI: 10.1080/00365521.2021.1988700] [Reference Citation Analysis]
24 Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213-219. [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
25 Kim DH, Kim B, Youn SY, Kim H, Choi JI. Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1763. [PMID: 34679461 DOI: 10.3390/diagnostics11101763] [Reference Citation Analysis]
26 Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826-834. [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
27 Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25:52-64. [PMID: 30360031 DOI: 10.3350/cmh.2018.0040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
28 Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, Cho EH, Choi CW, Kim KS, Hwang S, Kim JH, Chang AR, Park Y, Kim ES, Kim WC, Jo S, Park HJ. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy. Cancer. 2020;126:363-372. [PMID: 31747476 DOI: 10.1002/cncr.32502] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
29 Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology 2017;66:1454-63. [PMID: 28628942 DOI: 10.1002/hep.29321] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 13.4] [Reference Citation Analysis]
30 Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Dig Dis Sci. 2017;62:3235-3242. [PMID: 28983724 DOI: 10.1007/s10620-017-4775-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
31 Park EK, Kim HJ, Kim CY, Hur YH, Koh YS, Kim JC, Kim HJ, Kim JW, Cho CK. A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Ann Surg Treat Res 2014;87:72-80. [PMID: 25114886 DOI: 10.4174/astr.2014.87.2.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
32 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Lee S, Hyuck David Kwon C, Man Kim J, Joh JW, Woon Paik S, Kim BW, Wang HJ, Lee KW, Suh KS, Lee SK. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation. Liver Transpl. 2014;20:1057-1063. [PMID: 24862741 DOI: 10.1002/lt.23919] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
34 Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013; 19(3): 339-346 [PMID: 23372355 DOI: 10.3748/wjg.v19.i3.339] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
35 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 329] [Article Influence: 42.4] [Reference Citation Analysis]
36 Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, Kim JK, Lee do Y, Lee KH, Han KH. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int. 2011;31:369-376. [PMID: 21083802 DOI: 10.1111/j.1478-3231.2010.02368.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
37 Rhim H. Recent advance of local ablation for hepatocellular carcinoma. J Korean Med Assoc 2013;56:964. [DOI: 10.5124/jkma.2013.56.11.964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Lee WJ, Kim DY, Kim CM. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 2014;190:882-90. [PMID: 24638270 DOI: 10.1007/s00066-014-0643-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
39 Kang SJ, Kim UJ, Kim SE, An JH, Jang MO, Myung DS, Park KH, Jung SI, Cho SB, Jang HC, Joo YE. Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma. Dis Markers 2018;2018:9120878. [PMID: 29849829 DOI: 10.1155/2018/9120878] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Sohn A, Kim H, Yu SJ, Yoon JH, Kim Y. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. Anal Bioanal Chem 2017;409:2829-38. [PMID: 28168546 DOI: 10.1007/s00216-017-0227-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
41 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
42 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
43 Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009;15 Suppl 6:S50-S59. [PMID: 20037280 DOI: 10.3350/kjhep.2009.15.s6.s50] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
44 Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, Yoo BC. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2010;16:383-388. [PMID: 21415582 DOI: 10.3350/kjhep.2010.16.4.383] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
45 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
46 Song BG, Sinn DH, Chi S, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol. 2018;30:1447-1452. [PMID: 30063482 DOI: 10.1097/meg.0000000000001226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
47 Chen P, Furuse J, Han K, Hsu C, Lim H, Moon H, Qin S, Ye S, Yeoh E, Yeo W. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion: HCC clinical trials in Asia. Liver International 2010;30:1427-38. [DOI: 10.1111/j.1478-3231.2010.02292.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
48 Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology 2020;71:2023-32. [PMID: 31556128 DOI: 10.1002/hep.30973] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
49 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
50 Park JH, Yoon SM, Lim YS, Kim SY, Shim JH, Kim KM, Lee HC, Cho B, Park G, Kim JH. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:1638-1642. [PMID: 23621519 DOI: 10.1111/jgh.12249] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
51 Lee S, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma 2015;2:39-47. [PMID: 27508193 DOI: 10.2147/JHC.S79353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
52 Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
53 Bae BK, Park HC, Yoo GS, Choi MS, Oh JH, Yu JI. The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. Cancers 2022;14:2081. [DOI: 10.3390/cancers14092081] [Reference Citation Analysis]
54 Song DS, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2013; 19(29): 4679-4688 [PMID: 23922465 DOI: 10.3748/wjg.v19.i29.4679] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
55 Park YH, Kim BK, Kim JK, Kim HC, Kim DY, Park JY, Han K, Kim SU, Shin SH, Hahn KY, Ahn SH. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea: The outcomes of chronic hepatitis B. J Gastroenterol Hepatol 2014;29:1005-11. [DOI: 10.1111/jgh.12478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
56 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
57 Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol 2017;23:42-50. [PMID: 28263954 DOI: 10.3350/cmh.2016.0058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
58 Cha J, Seong J, Lee IJ, Kim JW, Han KH. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J. 2013;54:1178-1185. [PMID: 23918567 DOI: 10.3349/ymj.2013.54.5.1178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
59 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
60 Chon HY, Seo YS, Lee JI, Kim BS, Jang BK, Kim SG, Suk KT, Kim IH, Lee JW, Chon YE, Kim MY, Jeong SW, Lee HA, Yim SY, Um SH, Lee HW, Lee KS, Song JE, Lee CH, Chung WJ, Hwang JS, Yoo JJ, Kim YS, Kim DJ, Lee CH, Yu JH, Ha YJ, Kim MN, Lee JH, Hwang SG, Kang SH, Baik SK, Jang JY, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2021;33:885-93. [PMID: 32541238 DOI: 10.1097/MEG.0000000000001794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
62 Kim EJ, Yeon JE, Kwon OS, Lee HN, Shin SK, Kang SH, Byun KS, Kim JH, Kwon SY, Suh SJ, Yim HJ, Kim YS, Kim JH. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis. Dig Dis Sci 2017;62:808-16. [DOI: 10.1007/s10620-016-4431-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
63 Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10:e0124434. [PMID: 25923439 DOI: 10.1371/journal.pone.0124434] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
64 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. Korean J Intern Med 2020;35:65-78. [PMID: 31189301 DOI: 10.3904/kjim.2018.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
65 Lee JS, Kim JM, Lee S, Choi JY, Cho W, Choi GS, Park JB, Kwon CH, Kim SJ, Joh JW. The prognosis in cases of hepatocellular carcinoma after hepatectomy: young patients versus older patients. Korean J Hepatobiliary Pancreat Surg 2015;19:154-60. [PMID: 26693234 DOI: 10.14701/kjhbps.2015.19.4.154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
66 Ehman EC, Umetsu SE, Ohliger MA, Fidelman N, Ferrell LD, Yeh BM, Yee J, Hope TA. Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. Abdom Radiol (NY) 2016;41:2161-8. [PMID: 27484789 DOI: 10.1007/s00261-016-0837-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
67 Song DS, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol. 2012;18:258-267. [PMID: 23091805 DOI: 10.3350/cmh.2012.18.3.258] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
68 Kim SW, Oh D, Park HC, Lim DH, Shin SW, Cho SK, Gwak GY, Choi MS, Paik YH, Paik SW. Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiat Oncol J 2014;32:14-22. [PMID: 24724047 DOI: 10.3857/roj.2014.32.1.14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
69 Park HJ, Kim SH, Jang KM, Lim S, Kang TW, Park HC, Choi D. Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treated with radiotherapy in patients with chronic liver disease. AJR Am J Roentgenol. 2014;202:92-101. [PMID: 24370133 DOI: 10.2214/ajr.12.10212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
70 Kim KM, Kim J, Sinn DH, Kim HS, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment? Scand J Gastroenterol 2018;53:727-33. [PMID: 29609485 DOI: 10.1080/00365521.2018.1458895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Kwak H, Park J, Nam B, Yu A, Woo SM, Kim TH, Kim SH, Koh YH, Kim HB, Park SJ, Lee WJ, Hong EK, Kim C. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area: Outcomes and changes of the HCC cohort. J Gastroenterol Hepatol 2014;29:820-9. [DOI: 10.1111/jgh.12470] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
72 Ehman EC, Behr SC, Umetsu SE, Fidelman N, Yeh BM, Ferrell LD, Hope TA. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (NY) 2016;41:963-9. [PMID: 27193793 DOI: 10.1007/s00261-015-0623-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
73 Lee C, Yang JI, Byun HJ, Kang JM, Choi S, Yim JY. Status of primary liver cancer found through routine health check-up. J Korean Med Sci 2013;28:1449-53. [PMID: 24133348 DOI: 10.3346/jkms.2013.28.10.1449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci. 2018;63:1062-1071. [PMID: 29442276 DOI: 10.1007/s10620-018-4934-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
75 Choi MS, Sinn DH, Kim SA, Lee YS, Choi W, Paik SW. The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea: a multi-center, nation-wide, cross-sectional epidemiologic study. Gut Liver 2012;6:241-8. [PMID: 22570755 DOI: 10.5009/gnl.2012.6.2.241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
76 Xu X, Huang P, Tian H, Chen Y, Ge N, Tang W, Yang B, Xia J. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1273-8. [PMID: 24955456 DOI: 10.1111/jgh.12554] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
77 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
78 Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut Liver 2016;10:939-47. [PMID: 27282264 DOI: 10.5009/gnl15527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
79 Cho JY, Choi MS, Lee GS, Sohn W, Ahn J, Sinn DH, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clin Mol Hepatol 2016;22:477-86. [PMID: 28081587 DOI: 10.3350/cmh.2016.0048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
80 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
82 Lee JA, Lee TH, Kim JY, Seok MG, Kang MG, Jeong JH, Koo HS, Song KH, Kim YS, Kim SM, Huh KC, Choi YW, Kang YW. [Comparison of malnutrition risk between patients with liver cirrhosis and viral hepatitis carrier: a single center study]. Korean J Gastroenterol 2014;64:284-9. [PMID: 25420738 DOI: 10.4166/kjg.2014.64.5.284] [Reference Citation Analysis]
83 Park Y, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YE, Park JH, Lee YI, Yun HR, Han KH. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36:100-107. [PMID: 26013186 DOI: 10.1111/liv.12878] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
84 Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5811. [PMID: 28296720 DOI: 10.1097/md.0000000000005811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
85 Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, Kim JW, Nam TK, Kim K, Jang HS, Kim JH, Kim MS, Yoon WS, Jung I, Seong J. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 2017;37:90-100. [PMID: 27317941 DOI: 10.1111/liv.13191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
86 Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YN, Ahn SS, Han KH, Kim HS. Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. Medicine (Baltimore) 2016;95:e3328. [PMID: 27057911 DOI: 10.1097/MD.0000000000003328] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
87 Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84 Suppl 1:17-22. [PMID: 22156481 DOI: 10.1159/000333210] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
88 Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Outcomes after curative hepatectomy in patients with non-B non-C hepatocellular carcinoma and hepatitis B virus hepatocellular carcinoma from non-cirrhotic liver. J Surg Oncol 2014;110:976-81. [PMID: 25171344 DOI: 10.1002/jso.23772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
89 Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, Lim YS, Kim KM, Shim JH, Lee D. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35:232-239. [PMID: 24576055 DOI: 10.1111/liv.12516] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
90 Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015;62:694-701. [PMID: 25963803 DOI: 10.1002/hep.27889] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 11.1] [Reference Citation Analysis]
91 Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol 2015;30:1024-31. [PMID: 25611175 DOI: 10.1111/jgh.12898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
92 Kim SS, Lee S, Kim MJ. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma. Eur Radiol 2021;31:3405-16. [PMID: 33146795 DOI: 10.1007/s00330-020-07419-y] [Reference Citation Analysis]
93 Min YW, Lee JH, Gwak GY, Paik YH, Lee JH, Rhee PL, Koh KC, Paik SW, Yoo BC, Choi MS. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29:1043-1048. [PMID: 24863186 DOI: 10.1111/jgh.12504] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
94 Kong M, Hong SE. Optimal follow-up duration for evaluating objective response to radiotherapy in patients with hepatocellular carcinoma: a retrospective study. Chin J Cancer 2015;34:79-85. [PMID: 25418189 DOI: 10.5732/cjc.014.10136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
95 Jang JW, Yoo SH, Kwon JH, You CR, Lee S, Lee JH, Chung KW. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther. 2011;34:1337-1346. [PMID: 22007836 DOI: 10.1111/j.1365-2036.2011.04888.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
96 Kim YI, Park HC, Lim DH, Park HJ, Kang SW, Park SY, Kim JS, Han Y, Paik SW. Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 2012;30:189-96. [PMID: 23346538 DOI: 10.3857/roj.2012.30.4.189] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
97 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
98 Lee J, Sinn DH, Kim JH, Gwak GY, Kim HS, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. J Korean Med Sci 2015;30:1618-24. [PMID: 26539006 DOI: 10.3346/jkms.2015.30.11.1618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
99 Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, Park JY, Kim do Y, Ahn SH, Tak WY. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. J Gastroenterol Hepatol. 2014;29:1463-1469. [PMID: 25273508 DOI: 10.1111/jgh.12542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
100 Bae SH, Park HC, Lim DH, Lee JA, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:e603-e607. [PMID: 22208963 DOI: 10.1016/j.ijrobp.2011.09.053] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
101 Choi SI, Yu A, Kim BH, Ko EJ, Park SS, Nam BH, Park JW. A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. J Gastroenterol Hepatol 2017;32:651-8. [PMID: 27519171 DOI: 10.1111/jgh.13532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
102 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology 2021;74:603-12. [DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
103 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: An Eastern perspective. World J Gastroenterol 2015; 21(13): 3826-3842 [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
104 Yu JI, Park HC, Lim DH, Park W, Yoo BC, Paik SW, Koh KC, Lee JH. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci. 2011;26:1014-1022. [PMID: 21860551 DOI: 10.3346/jkms.2011.26.8.1014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
105 Cha H, Park HC, Yu JI, Kim TH, Nam TK, Yoon SM, Yoon WS, Kim JW, Kim MS, Jang HS, Choi Y, Kim JH, Kay CS, Jung I, Seong J. Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). Cancer Res Treat. 2017;49:61-69. [PMID: 27338036 DOI: 10.4143/crt.2016.097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
106 Kim YW, Kwon JH, Chung E, Lee SW, Lee JY, Jang JW, Chung KW, Nam SW. Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2015;2015:181065. [PMID: 25878659 DOI: 10.1155/2015/181065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
107 Choi JY. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. Oncology. 2011;81 Suppl 1:141-147. [PMID: 22212948 DOI: 10.1159/000333277] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
108 Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han K. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120-7. [DOI: 10.1111/j.1478-3231.2012.02811.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
109 Kim KH, Kim MS, Chang JS, Han KH, Kim do Y, Seong J. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34:784-794. [PMID: 24330457 DOI: 10.1111/liv.12436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
110 Kim SM, Heo SH, Kim JW, Lim HS, Shin SS, Jeong YY, Kang HK. Hepatic arterial phase on gadoxetic acid-enhanced liver MR imaging: a randomized comparison of 0.5 mL/s and 1 mL/s injection rates. Korean J Radiol 2014;15:605-12. [PMID: 25246821 DOI: 10.3348/kjr.2014.15.5.605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
111 Park YK, Song SK, Kim BW, Park SK, Chung CW, Wang HJ. Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma. World J Surg Oncol 2017;15:225. [PMID: 29258507 DOI: 10.1186/s12957-017-1292-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
112 Yim SY, Seo YS, Jung CH, Kim TH, Lee JM, Kim ES, Keum B, Jong YK, An H, Kim JH, Yim HJ, Kim DS, Jeen YT, Yeon JE, Lee HS, Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS. The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years? Liver Int. 2016;36:445-453. [PMID: 26352789 DOI: 10.1111/liv.12960] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
113 Jihye C, Jinsil S. Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer 2012;1:216-25. [PMID: 24159586 DOI: 10.1159/000343836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
114 Kim BK, Oh HJ, Park JY, Kim do Y, Ahn SH, Han KH, Park Y, Yoo EJ, Park YN, Kim SU. Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. Liver Int. 2013;33:180-189. [PMID: 23295050 DOI: 10.1111/liv.12020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
115 Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim H. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int 2017;37:879-87. [DOI: 10.1111/liv.13341] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
116 Kim YI, Kim HS, Park JW. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. PLoS One. 2016;11:e0157299. [PMID: 27304617 DOI: 10.1371/journal.pone.0157299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
117 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
118 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-78] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 6.8] [Reference Citation Analysis]
119 Bajpai S, Kambadakone A, Guimaraes AR, Arellano RS, Gervais DA, Sahani D. Image-guided Treatment in the Hepatobiliary System: Role of Imaging in Treatment Planning and Posttreatment Evaluation. RadioGraphics 2015;35:1393-418. [DOI: 10.1148/rg.2015140281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
120 Kim YC, Kim YH, Um SH, Seo YS, Park EK, Oh SY, Han YM, Choe JG. Usefulness of Bremsstrahlung Images after Intra-arterial Y-90 Resin Microphere Radioembolization for Hepatic Tumors. Nucl Med Mol Imaging. 2011;45:59-67. [PMID: 24899979 DOI: 10.1007/s13139-010-0066-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
121 Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int. 2014;34:795-801. [PMID: 24350564 DOI: 10.1111/liv.12445] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
122 Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014;29:1699-1705. [PMID: 24730702 DOI: 10.1111/jgh.12612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
123 Park Y, Lee JH, Sinn DH, Park JY, Kim MA, Kim YJ, Yoon JH, Kim DY, Ahn SH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clin Transl Gastroenterol 2021;12:e00290. [PMID: 33433118 DOI: 10.14309/ctg.0000000000000290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-51. [PMID: 32492765 DOI: 10.3350/cmh.2020.0004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
125 Kim KM, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016;36:1490-1497. [PMID: 26936471 DOI: 10.1111/liv.13107] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
126 Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Liver Cancer Working Group report. Jpn J Clin Oncol. 2010;40 Suppl 1:i19-i27. [PMID: 20870915 DOI: 10.1093/jjco/hyq123] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
127 Lim Y, Han S, Heo N, Shim JH, Lee HC, Suh DJ. Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine. Gastroenterology 2014;147:152-61. [DOI: 10.1053/j.gastro.2014.02.033] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 12.6] [Reference Citation Analysis]
128 Kim BH, Park JW, Kim JS, Lee SK, Hong EK. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma. Gut Liver. 2019;13:342-348. [PMID: 30600675 DOI: 10.5009/gnl18345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
129 Kong M, Hong SE, Choi WS, Choi J, Kim Y. Treatment outcomes of helical intensity-modulated radiotherapy for unresectable hepatocellular carcinoma. Gut Liver. 2013;7:343-351. [PMID: 23710317 DOI: 10.5009/gnl.2013.7.3.343] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
130 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
131 Kim HY, Park J. Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone. Dig Dis 2011;29:303-9. [DOI: 10.1159/000327563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
132 Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-4787. [PMID: 21469082 DOI: 10.1002/cncr.26099] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
133 Jeon MY, Kim HS, Lim TS, Han DH, Kim BK, Park JY, Kim DY, Ahn SH, Choi GH, Choi JS, Han KH, Kim SU. Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. PLoS One 2019;14:e0214613. [PMID: 30947275 DOI: 10.1371/journal.pone.0214613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Yoon HI, Jung I, Han KH, Seong J. The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. Oncotarget 2016;7:62715-25. [PMID: 27486881 DOI: 10.18632/oncotarget.10908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Kim JY, Lim YK, Kim TH, Cho KH, Choi SH, Jeong H, Kim DW, Park JH, Shin DH, Lee SB, Kim SS, Kim JY, Kim DY, Park JW. Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. Acta Oncol 2015;54:1827-32. [PMID: 25765526 DOI: 10.3109/0284186X.2015.1009637] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
136 Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011;26:1612-1618. [PMID: 21517968 DOI: 10.1111/j.1440-1746.2011.06751.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
137 Shin SK, Kim YS, Shim YS, Choi SJ, Park SH, Jung DH, Kwon OS, Choi DJ, Kim JH. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore) 2017;96:e7761. [PMID: 28816953 DOI: 10.1097/MD.0000000000007761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
138 Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, Park CH, Kim HS, Choi SK, Rew JS. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) 2017;96:e6745. [PMID: 28445298 DOI: 10.1097/MD.0000000000006745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
139 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
140 Kim JH, Min YW, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The utility of gadoxetic acid-enhanced magnetic resonance imaging in the surveillance for postoperative recurrence of hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e5666. [PMID: 28002336 DOI: 10.1097/MD.0000000000005666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
141 Na JE, Sinn DH, Lee JH, Jang HJ, Baek SY, Kim KA, Kang WS, Gwak GY, Paik YH, Kim YJ, Choi MS, Yoon JH, Lee JH, Koh KC, Paik SW. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat 2021. [PMID: 34251707 DOI: 10.1111/jvh.13572] [Reference Citation Analysis]
142 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
143 Song HY, Lee HK, Lee JS, Kim JY, Yim YH, Song TJ, Bae WK, Kim NH, Kim KA. Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med 2012;27:47-52. [PMID: 22403499 DOI: 10.3904/kjim.2012.27.1.47] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
144 Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yeon JE, Byun KS, Kim HS, Kim JH, Kim SU. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer 2019;19:363. [PMID: 30991968 DOI: 10.1186/s12885-019-5495-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
145 Jha AK, Mithun S, Purandare NC, Shah SA, Agrawal A, Kulkarni SS, Shetty N, Rangarajan V. Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy. Nucl Med Commun 2016;37:917-23. [PMID: 27182686 DOI: 10.1097/MNM.0000000000000544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
146 Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han K, Baek S, Kim HS, Kim SU, Park MS. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. Liver Int 2018;38:1655-63. [DOI: 10.1111/liv.13731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
147 Kim HY, Park J, Joo J, Kim H, Woo SM, Lee WJ, Kim C. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma: Outcome of sorafenib therapy in cirrhosis. J Gastroenterol Hepatol 2013;28:1756-61. [DOI: 10.1111/jgh.12310] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
148 Yu JI, Park HC, Lim do H, Kim CJ, Oh D, Yoo BC, Paik SW, Kho KC, Lee JH. Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci. 2012;27:736-743. [PMID: 22787367 DOI: 10.3346/jkms.2012.27.7.736] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
149 Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee JH, Yu SJ, Kim YJ, Yoon JH, Cho EJ, Kim SU. Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. Gut Liver 2020;14:477-85. [PMID: 31640304 DOI: 10.5009/gnl19111] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Kim HY, Park JW, Joo J, Jung SJ, An S, Woo SM, Kim HB, Koh YH, Lee WJ, Kim CM. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1051-1056. [PMID: 22098152 DOI: 10.1111/j.1440-1746.2011.06963.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
151 Kwon OS, Jung YK, Kim YS, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS, Chun BC, Kim JH. Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol. 2010;16:308-314. [PMID: 20924214 DOI: 10.3350/kjhep.2010.16.3.308] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
152 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
153 Shin SH, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int. 2015;35:1054-1062. [PMID: 24930484 DOI: 10.1111/liv.12621] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
154 Gong SC, Cho MY, Lee SW, Kim SH, Kim MY, Baik SK. The meaning of gross tumor type in the aspects of cytokeratin 19 expression and resection margin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:206-12. [PMID: 26212571 DOI: 10.1111/jgh.13063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Dionisi F, Ben-josef E. The Use of Proton Therapy in the Treatment of Gastrointestinal Cancers: Liver. The Cancer Journal 2014;20:371-7. [DOI: 10.1097/ppo.0000000000000082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
156 Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60:686-693. [PMID: 22906998 DOI: 10.1016/j.cyto.2012.07.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 6.5] [Reference Citation Analysis]
157 Eun HS, Kim MJ, Kim HJ, Ko KH, Moon HS, Lee ES, Kim SH, Lee HY, Lee BS. The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care. Korean J Hepatol 2011;17:189-98. [PMID: 22102385 DOI: 10.3350/kjhep.2011.17.3.189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
158 Sohn W, Choi MS, Cho JY, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors. Gut Liver. 2014;8:543-551. [PMID: 25071073 DOI: 10.5009/gnl13356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
159 Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL. Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620. [PMID: 21062497 DOI: 10.1186/1471-2407-10-620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
160 Kim JH, Sinn DH, Gwak GY, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim KY, Kim K, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: A retrospective cohort study. Medicine (Baltimore) 2016;95:e4735. [PMID: 27583916 DOI: 10.1097/MD.0000000000004735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Hwang S, Ahn C, Kim K, Moon D, Ha T, Song G, Jung D, Park G, Yu Y, Park P, Choi Y, Kim K, Lim Y, Lee HC, Yu E, Lee S. Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation. J Gastrointest Surg 2011;15:971-81. [DOI: 10.1007/s11605-011-1467-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
162 Kim JY, Sinn DH, Gwak GY, Choi GS, Saleh AM, Joh JW, Cho SK, Shin SW, Carriere KC, Ahn JH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clin Mol Hepatol 2016;22:250-8. [PMID: 27377909 DOI: 10.3350/cmh.2016.0015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
163 Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer. 2013;13:335. [PMID: 23829392 DOI: 10.1186/1471-2407-13-335] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
164 Choi SI, Cho Y, Ki M, Kim BH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Hong EK, Kim CM, Park JW. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS One 2022;17:e0265668. [PMID: 35324973 DOI: 10.1371/journal.pone.0265668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Bae SH, Park HC, Yoon WS, Yoon SM, Jung IH, Lee IJ, Kim JW, Seong J, Kim TH, Nam TK, Choi Y, Lee SY, Jang HS, Lee DS, Kim JH. Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05). Cancer Res Treat 2019;51:1589-99. [PMID: 30971065 DOI: 10.4143/crt.2018.687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
166 Lee K, Sinn DH, Gwak GY, Cho HC, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut Liver. 2016;10:796-802. [PMID: 27114418 DOI: 10.5009/gnl15368] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
167 Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, Lee WJ, Park SJ, Kim DY, Kim CM. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190:806-814. [PMID: 24589917 DOI: 10.1007/s00066-014-0604-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
168 Chen S, Jin H, Dai Z, Wei M, Xiao H, Su T, Li B, Liu X, Wang Y, Li J, Shen S, Zhou Q, Peng B, Peng Z, Peng S. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Cancer Med 2019;8:1530-9. [PMID: 30864247 DOI: 10.1002/cam4.2038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
169 Min YW, Kim J, Kim S, Sung YK, Lee JH, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW. Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liver Int. 2013;33:197-202. [PMID: 23295052 DOI: 10.1111/liv.12023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
170 Kim HS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Park YN, Han DH, Kim KS, Choi JS, Choi GH, Kim HS. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. Clin Mol Hepatol. 2020;26:33-44. [PMID: 31243939 DOI: 10.3350/cmh.2018.0073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
171 Suh YG, Kim DY, Han KH, Seong J. Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice. Gut Liver 2014;8:526-35. [PMID: 25071072 DOI: 10.5009/gnl13370] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
172 Lee J, Lee Y, Park K, Hwang D, Lee JH, Song KB. Anatomical Resection But Not Surgical Margin Width Influence Survival Following Resection for HCC, A Propensity Score Analysis. World J Surg 2016;40:1429-39. [DOI: 10.1007/s00268-016-3421-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
173 Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee CH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Lee JH, Kim SU. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2020;32:378-385. [PMID: 32011388 DOI: 10.1097/meg.0000000000001512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
174 Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol 2017; 9(14): 645-656 [PMID: 28588749 DOI: 10.4254/wjh.v9.i14.645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
175 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
176 Paik N, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, Gwak G, Paik Y, Choi MS, Lee JH, Koh KC, Paik SW. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int 2018;38:68-75. [DOI: 10.1111/liv.13489] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
177 Kim Y, Park J, Kwak H, Kim BH, Lee JH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Kim C. Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. Liver Int 2014;34:1278-86. [DOI: 10.1111/liv.12535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
178 Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH. Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area. Liver Cancer 2016;5:21-36. [PMID: 26989657 DOI: 10.1159/000367756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
179 Kwon OS, Jung YK, Bae KS, Kim JH, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS. Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: a case-control study. Alcohol 2012;46:537-41. [PMID: 22572059 DOI: 10.1016/j.alcohol.2012.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
180 Yun WK, Choi MS, Choi D, Rhim HC, Joh JW, Kim KH, Jang TH, Lee JH, Koh KC, Paik SW, Yoo BC. Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation. Hepatol Int 2011;5:722-9. [PMID: 21484104 DOI: 10.1007/s12072-010-9237-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
181 Kim DY, Kim HJ, Jeong SE, Kim SG, Kim HJ, Sinn DH, Lee YJ, Jeong WK, Choi KS, Heo N, Kim DJ, Kim YS, Kim YB, Kim YJ, Kim H, Park M, Lee CW, Tak WY, Chung JH, Kim SY, Kim Y, Lee W, Kim HS. The Korean guideline for hepatocellular carcinoma surveillance. J Korean Med Assoc 2015;58:385. [DOI: 10.5124/jkma.2015.58.5.385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
182 Song JH, Goh MJ, Park Y, Oh JH, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scand J Gastroenterol 2021;56:274-80. [PMID: 33399022 DOI: 10.1080/00365521.2020.1866063] [Reference Citation Analysis]
183 Lee SS, Byoun YS, Jeong SH, Kim YM, Gil H, Min BY, Seong MH, Jang ES, Kim JW. Type and cause of liver disease in Korea: single-center experience, 2005-2010. Clin Mol Hepatol. 2012;18:309-315. [PMID: 23091812 DOI: 10.3350/cmh.2012.18.3.309] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
184 Jang JY, Kim MY, Jeong SW, Kim TY, Kim SU, Lee SH, Suk KT, Park SY, Woo HY, Kim SG, Heo J, Baik SK, Kim HS, Tak WY. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol. 2013;19:1-16. [PMID: 23593604 DOI: 10.3350/cmh.2013.19.1.1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
185 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PMID: 25752327 DOI: 10.1111/liv.12818] [Cited by in Crossref: 369] [Cited by in F6Publishing: 383] [Article Influence: 52.7] [Reference Citation Analysis]
186 Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158-164. [PMID: 22212951 DOI: 10.1159/000333280] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
187 Park JG. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 2015;21:287-294. [PMID: 26527250 DOI: 10.3350/cmh.2015.21.3.287] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
188 Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336-1342. [PMID: 22314421 DOI: 10.1016/j.jhep.2012.01.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 111] [Article Influence: 10.1] [Reference Citation Analysis]